The USP dissolution test was used to select seven products with a wide range of dissolution characteristics for in vivo examination. The bioequivalence of seven (500 mg) products was evaluated in two crossover urinary excretion experiments. In each study three products were compared with the innovat
In vitro and in vivo bioequivalence of commerical prednisone tablets
β Scribed by G. E. Francisco; I. L. Honigberg; J. T. Stewart; J. A. Kotzan; W. J. Brown; W. L. Schary; F. R. Pelsor; V. P. Shah
- Publisher
- John Wiley and Sons
- Year
- 1984
- Tongue
- English
- Weight
- 433 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0142-2782
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract A 500 mg dose of naproxen in a caplet formulation (product A) or a tablet (Naprosyn 500, product B) was administered to 14 fasting healthy subjects on two separate occasions, separated by a 1β2 week washout period in an open, randomized crossover. Blood samples were drawn periodically a
Four 50 mg and three 100 mg marketed nitrofurantoin tablets were studied in 14 healthy male subjects. Urine was collected 1, 2, 3, 4, 6, 8, 12, and 23 h after each dose, and nitrofurantoin was assayed by HPLC. The in vitro dissolution of the tablets was determined using USP Apparatus 1 and 2, with 0
The bioavailability of potassium from orally administered potassium tartrate was evaluated in 20 normal subjects under metabolic balance conditions. Subjects were given 34 mmol potassium (5 tablets of Cal-K@) as a divided dose on each of 2 consecutive days. Urinary excretion of potassium, as determi